SenzaGen has been selected to test compounds from H. Lundbeck A/S. Valued at SEK 0.4 million, the project includes both GARD®skin and GARD®air. The tests will be performed in SenzaGen’s GLP-certified laboratory in Lund.

A new collaboration is being announced with H. Lundbeck A/S, a global pharmaceutical company covering the full value chain from research and development to production and promotion of treatments of disorders within CNS. The company aims to use the combination of GARD tests, which SenzaGen is unique in being able to offer, to determine whether new development candidates have sensitizing properties.

“In spite of the challenges presented by the ongoing pandemic, we continue to establish the GARD technology among international customers. We are very pleased that after a thorough evaluation based on several interactions and presentations, Lundbeck has chosen to collaborate with SenzaGen and that they have decided to test compounds with both GARDair and GARDskin. The order illustrates that our direct contacts with large international companies continue to bear fruit, and means that we, during the year, will have run tests for customers in all the major industries we cater to – pharmaceuticals, medical devices, cosmetics and chemicals,” says Axel Sjöblad, CEO of SenzaGen.

“Lundbeck is pleased to initiate this collaboration with SenzaGen. The introduction of new innovative assays such as the GARD tests is part of our commitment to constantly expand our expertise in safety testing. By doing this, we pursue our goals of providing a safe and healthy work environment for our employees and improving the quality of life for people living with brain disorders,” says Allan Dahl Rasmussen, Director of Regulatory Toxicology in Lundbeck.

With excellent predictivity, the GARD® technology improves the quality of customers’ decision-making and contributes to increased product safety while reducing the number of animal tests.

Contacts

Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com| Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com| Mobile: +46 708-20 29 44

About us

SenzaGen is a Swedish biotech company that provides state-of-the-art animal-free tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen’s GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. 

Attachments

SenzaGen receives SEK 0.4 m order for GARD®skin and GARD®air tests from pharmaceutical company H. Lundbeck A/S

© Modular Finance, source Nordic Press Releases